Day: November 10, 2022

Comparative efficacy of three 2′-fluoropyrimidine nucleosides and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (BW B759U) against pseudorabies and equine rhinopneumonitis virus infection in vitro and in laboratory animals was written by Rollinson, Elizabeth A.. And the article was included in Antiviral Research on January 31,1987.Product Details of 69256-17-3 The following contents are mentioned in the article:

The 3 2′-fluoropyrimidine nucleosides 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) [69123-90-6], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (FIAU) [69123-98-4], and 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluracil (FMAU) [69256-17-3], showed high activity in RK13 monolayers against equine rhinopneumonitis virus, (EHV-1), Aujeszky’s disease virus (SHV-1, pseudorabies), and infectious bovine rhinotracheitis virus (1BR, BHV-1). The activity of these compounds was compared with 9-(1,3-dihydroxy-2-propoxymethyl)guanine (BW B759U, DHPG) in 2 laboratory animal disease models: EHV-1-induced hepatitis in hamsters and SHV-1-induced encephalitis in mice. All the compounds, provided from 3 to 5 h pre-infection for 5 days, were effective in preventing EHV-1 mortality (at 3-5 mg/kg per day) and in significantly reducing SHV-1 mortality (at 60 mg/kg per day). While FIAU had the greatest activity in vitro, FMAU tended to be more potent in vivo. The reasons for these differences between relative in vitro and in vivo activities are briefly discussed. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Product Details of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Product Details of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Activity of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil against simian varicella virus infections in African green monkeys was written by Soike, Kenneth F.; Cantrell, Connie; Gerone, Peter J.. And the article was included in Antimicrobial Agents and Chemotherapy on January 31,1986.Category: pyrimidines The following contents are mentioned in the article:

The fluorinated pyrimidines 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil (FIAU) [69123-98-4] and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluracil (FMAU) [69256-17-3] are highly effective inhibitors of herpesvirus infections in vitro and in vivo. This report is concerned with an evaluation of their activities in African green monkeys (Cercopithecus aethiops) infected with simian varicella virus, a herpesvirus closely related to human varicella-zoster virus. Oral or i.v. administration of FIAU at 50 mg/kg daily as divided doses beginning 48 h after virus inoculation prevented the development of evidences of clin. infection. Oral treatment with FIAU at 30 mg/kg daily deferred as late as 7 days after virus inoculation modified the course of the disease. When treatment was started 48 h after virus inoculation, daily doses of FIAU as small as 1 mg/kg inhibited development of infections; daily doses of 0.2 mg/kg were ineffective. At the latter dose, FMAU prevented development of clin. disease, suggesting that it was more active than FIAU. No signs of FIAU toxicity were observed, with the single exception of an early but transitory elevation in aspartate aminotransferase activity in serum. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Category: pyrimidines).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Category: pyrimidines

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase was written by Jordan, Paul C.; Stevens, Sarah K.; Tam, Yuen; Pemberton, Ryan P.; Chaudhuri, Shuvam; Stoycheva, Antitsa D.; Dyatkina, Natalia; Wang, Guangyi; Symons, Julian A.; Deval, Jerome; Beigelman, Leo. And the article was included in ACS Chemical Biology on January 20,2017.Safety of 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one The following contents are mentioned in the article:

Human respiratory syncytial virus (RSV) is a neg.-sense RNA virus and a significant cause of respiratory infection in infants and the elderly. No effective vaccines or antiviral therapies are available for the treatment of RSV. ALS-8176 is a first-in-class nucleoside prodrug inhibitor of RSV replication currently under clin. evaluation. ALS-8112, the parent mol. of ALS-8176, undergoes intracellular phosphorylation, yielding the active 5′-triphosphate metabolite. The host kinases responsible for this conversion are not known. Therefore, elucidation of the ALS-8112 activation pathway is key to further understanding its conversion mechanism, particularly given its potent antiviral effects. Here, we have identified the activation pathway of ALS-8112 and show it is unlike other antiviral cytidine analogs. The first step, driven by deoxycytidine kinase (dCK), is highly efficient, while the second step limits the formation of the active 5′-triphosphate species. ALS-8112 is a 2′- and 4′-modified nucleoside analog, prompting us to investigate dCK recognition of other 2′- and 4′-modified nucleosides. Our biochem. approach along with computational modeling contributes to an enhanced structure-activity profile for dCK. These results highlight an exciting potential to optimize nucleoside analogs based on the second activation step and increased attention toward nucleoside diphosphate and triphosphate prodrugs in drug discovery. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Safety of 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Safety of 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Mutagenic potential of anti-herpes agents was written by De Clercq, E.; Cassiman, J. J.. And the article was included in Life Sciences on January 20,1986.Reference of 69256-17-3 The following contents are mentioned in the article:

A number of anti-herpes agents which are either licensed for clin. use (acyclovir  [59277-89-3]) or subject to clin. studies ((E)-5-(2-bromovinyl)-2′-deoxyuridine  [69304-47-8], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl-5-iodocytosine  [69123-90-6], and 9-(1,3-dihydroxy-2-propoxymethyl)guanine  [82410-32-0]) or under preclin. investigation (1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (FIAU) [69123-98-4], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluracil  [69256-17-3], 9-(3,4-dihydroxybutyl)guanine  [83470-64-8], (E)-5-(2-bromovinyl)-2′-deoxycytidine  [74131-09-2], (E)-5-(bromovinyl)-1-β-D-arabinofuranosyluracil  [77181-69-2], carbocyclic bromovinyldeoxyuridine  [95463-56-2], (E)-5-(2-bromovinyl)uracil  [69304-49-0], and (E)-5-(2-bromovinyl)uridine  [86391-68-6]) were evaluated for their ability to induce sister chromatid exchange (SCE), an indicator of mutagenesis. SCE was scored on metaphasic chromosomes of human lymphocytes which had been exposed to 5-bromo-2-deoxyuridine and varying concentrations of the test compounds The antiviral assays were based on the inhibition of the cytopathogenicity of herpes simplex virus for human diploid fibroblasts. Most compounds, e.g., acyclovir, bromovinyldeoxyuridine, or carbocyclic bromovinyldeoxyuridine, either did not induce SCE or only did so at concentrations far above their min. antiviral concentrations However, FIAU and dihydroxypropoxymethylguanine affected the SCE rate at a concentration (≥4.5 μg/mL) that is readily achievable in blood following i.v. injection. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Reference of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Reference of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Activities of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2 was written by Schinazi, Raymond F.; Fox, Jack J.; Watanabe, Kyoichi A.; Nahmias, Andre J.. And the article was included in Antimicrobial Agents and Chemotherapy on January 31,1986.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one The following contents are mentioned in the article:

As measured by plaque and yield reduction assays, several metabolites of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) were highly active against herpes simplex virus types 1 and 2. These metabolites included the 2′-deoxy-2′-fluoroarabinosyl derivatives of 5-iodouracil, cytosine, uracil, and thymine. In mice inoculated intracerebrally with herpes simplex virus type 2, the relative order of potency of these compounds and known antiviral drugs were as follows: 2′-fluoro-5-methylarabinosyluracil (FMAU) [69256-17-3] ≫ 2′-fluoro-5-iodoarabinosylcytosine (FIAC) [69123-90-6] ≈ 2′-fluoro-5-iodoarabinosyluracil (FIAU) [69123-98-4] > acyclovir ≈ vidarabine ≫ 2′-fluoroarabinosylcytosine (FAC) [56632-83-8] ≈ 2′-fluoroarabinosyluracil (FAU) [69123-94-0]. One of the main metabolites of FMAU, 2′-fluoro-5-hydroxymethylarabinosyluracil  [94817-51-3], was essentially inactive in vivo. FIAC-, FIAU-, FMAU-, FAC-, and FAU-resistant herpes simplex virus variants prepared in cell culture were found to be (i) devoid of viral thymidine kinase  [9002-06-6], (ii) cross-resistant to one another and resistant to drugs requiring viral thymidine kinase for activation, and (iii) sensitive to vidarabine or phosphonoformate. These results indicate that FIAC, FIAU, and FMAU require the virally encoded thymidine kinase for activation and suggest that the antiviral activity of FAU and FAC in cell cultures is also mediated by this enzyme. The interaction of the fluoroarabinosylpyrimidine nucleosides with herpes simplex virus thymidine kinase in a cell-free system is also described. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Activities of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2 was written by Schinazi, Raymond F.; Fox, Jack J.; Watanabe, Kyoichi A.; Nahmias, Andre J.. And the article was included in Antimicrobial Agents and Chemotherapy on January 31,1986.Electric Literature of C10H13FN2O5 The following contents are mentioned in the article:

As measured by plaque and yield reduction assays, several metabolites of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine (FIAC) were highly active against herpes simplex virus types 1 and 2. These metabolites included the 2′-deoxy-2′-fluoroarabinosyl derivatives of 5-iodouracil, cytosine, uracil, and thymine. In mice inoculated intracerebrally with herpes simplex virus type 2, the relative order of potency of these compounds and known antiviral drugs were as follows: 2′-fluoro-5-methylarabinosyluracil (FMAU) [69256-17-3] ≫ 2′-fluoro-5-iodoarabinosylcytosine (FIAC) [69123-90-6] ≈ 2′-fluoro-5-iodoarabinosyluracil (FIAU) [69123-98-4] > acyclovir ≈ vidarabine ≫ 2′-fluoroarabinosylcytosine (FAC) [56632-83-8] ≈ 2′-fluoroarabinosyluracil (FAU) [69123-94-0]. One of the main metabolites of FMAU, 2′-fluoro-5-hydroxymethylarabinosyluracil  [94817-51-3], was essentially inactive in vivo. FIAC-, FIAU-, FMAU-, FAC-, and FAU-resistant herpes simplex virus variants prepared in cell culture were found to be (i) devoid of viral thymidine kinase  [9002-06-6], (ii) cross-resistant to one another and resistant to drugs requiring viral thymidine kinase for activation, and (iii) sensitive to vidarabine or phosphonoformate. These results indicate that FIAC, FIAU, and FMAU require the virally encoded thymidine kinase for activation and suggest that the antiviral activity of FAU and FAC in cell cultures is also mediated by this enzyme. The interaction of the fluoroarabinosylpyrimidine nucleosides with herpes simplex virus thymidine kinase in a cell-free system is also described. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Electric Literature of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Electric Literature of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

An improved procedure for the preparation of aromatic heterocyclic N-oxides was written by Rhie, Soo Young; Ryu, Eung K.. And the article was included in Heterocycles on February 1,1995.Reference of 35139-67-4 The following contents are mentioned in the article:

Nitrogen-containing heterocyclic compounds gave their N-oxides in excellent yields by reaction with m-chloroperbenzoic acid in DMF/MeOH in the presence of HF. The presence of HF and MeOH is crucial for the reaction. This study involved multiple reactions and reactants, such as 2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4Reference of 35139-67-4).

2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Reference of 35139-67-4

35139-67-4;2,6-Diamino-4-chloropyrimidine-1-oxide;The future of 35139-67-4;New trend of C4H5ClN4O;function of 35139-67-4

C2′-F Stereoconfiguration As a Puckering Switch for Base Stacking at the Dinucleotide Level was written by Moriou, Celine; Da Silva, Adilson D.; Vianelli Prado, Marcos Joel; Denhez, Clement; Plashkevych, Oleksandr; Chattopadhyaya, Jyoti; Guillaume, Dominique; Clivio, Pascale. And the article was included in Journal of Organic Chemistry on February 16,2018.Electric Literature of C10H13FN2O5 The following contents are mentioned in the article:

Fluorine configuration at C2′ of the bis(2′-fluorothymidine) dinucleotide is demonstrated to drive intramol. base stacking. 2′-β F-Configuration drastically reduces stacking compared to the 2′-α series. Hence, base stacking emerges as being tunable by the C2′-F stereoconfiguration through dramatic puckering variations scrutinized by NMR and natural bond orbital anal. Accordingly, 2′-β F-isomer photoreactivity is significantly reduced compared to that of the 2′-α F-isomer. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Electric Literature of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.Electric Literature of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases was written by Niedzwicki, John G.; El Kouni, Mahmoud H.; Chu, Shih Hsi; Cha, Sungman. And the article was included in Biochemical Pharmacology on February 1,1983.Category: pyrimidines The following contents are mentioned in the article:

Eighty-seven pyrimidine base and nucleoside analogs were evaluated as inhibitors of uridine phosphorylase (UrdPase) [289-95-2] and thymidine phosphorylase (dThdPase) [9030-23-3]. These findings, together with an extensive literature review, have allowed construction of structure-activity relationships for the binding of ligands to UrdPase and dThdPase and provide a basis for the rational design of new inhibitors of these enzymes. Addnl., 2,6-pyridinediol  [626-06-2] and 6-benzyl-2-thiouracil  [6336-50-1] were identified as being potent inhibitors of UrdPase and dThdPase, resp. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Category: pyrimidines).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Category: pyrimidines

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus was written by Machida, Haruhiko; Kuninaka, Akira; Yoshino, Hiroshi. And the article was included in Antimicrobial Agents and Chemotherapy on February 28,1982.Synthetic Route of C10H13FN2O5 The following contents are mentioned in the article:

Thymidine analogs highly active against herpes simplex virus were compared in their inhibitory action against 7 strains of varicella-zoster virus by a plaque reduction assay. E-5-bromovinyl-arabinosyluracil (I) [77181-69-2] was most active, followed by E-5-chlorovinyl-arabinosyluracil  [77181-70-5], E-5-bromovinyl-2′-deoxyuridine (II) [69304-47-8], 2′-fluoro-5-methyl-arabinosyluracil  [69256-17-3], 2′-fluoro-5-iodo-arabinosylcytosine  [69123-90-6], arabinosylthymine  [605-23-2], 5-vinyl-arabinosyluracil  [74886-33-2], acycloguanosine  [59277-89-3], and 5-iodo-2′-deoxyuridine  [54-42-2], in order of decreasing activity. I was >10-fold as active as II and almost completely inhibited plaque development of 5 strains of varicella-zoster virus at a concentration as low as 1 ng/mL. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Synthetic Route of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Synthetic Route of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3